-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer is a malignant tumor arising from the prostate.
Astellas Pharma announced today that the European Medicines Management Agency (EMA) Committee of medicines for human use (CHMP) for XTANDI (enzalutamide) application for metastatic hormone-sensitive prostate cancer (mHSPC) adopted a positive opinion of the treatment.
management
If approved by the European Medicines Agency (EMA), enzalutamide will be the only MEA approved for the treatment of three different types of advanced prostate cancer-non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC Oral treatment.
The CHMP decision is based on data from the pivotal Phase III ARCHES trial.
The CHMP decision is based on data from the pivotal Phase III ARCHES trial.
Original source:
Original source:href="" target="_blank" rel="noopener">leave a message here